Moloney murine leukemia virus reverse transcriptase (in context of Prime editor) (M-MLV RT)

The "Prime editor reverse transcriptase" most commonly refers to the Moloney murine leukemia virus reverse transcriptase (M-MLV RT), an enzyme that catalyzes the synthesis of DNA from an RNA template[2][3][9][10]. In the context of prime editing, it is not a standalone therapeutic target, but rather a functional module fused to a Cas9 nickase protein to form the core of the prime editor system. This chimeric protein, guided by a prime editing guide RNA (pegRNA), enables precise, programmable gene editing without inducing double-strand DNA breaks. The prime editor system uses the reverse transcriptase to copy the intended genetic change from the pegRNA template directly into the target DNA, expanding the range of possible genomic modifications over traditional CRISPR or base editor technologies. The primary molecular role is thus as an enzymatic tool for synthetic genome modification, not as a biological receptor, enzyme, or direct drug target[2][3][5][7][9]. **Key conventions and caveats:** - The “reverse transcriptase” in “Prime editor reverse transcriptase” is not a standalone protein in biology nor is it directly a traditional drug target; rather, it is an enzymatic component artificially used within the engineered genome-editing complex termed "prime editor"[2][3][7]. - This protein is almost always derived from M-MLV RT for prime editing systems[2][7][9][10]. - It is not a receptor, transporter, or therapeutic enzyme by itself, nor is it associated with direct ligand pharmacology (no known interacting drugs outside of generic RT inhibitors, which are irrelevant in this context). - **This entry should be marked as "is_incorrect: true"** for "prime editor reverse transcriptase" as a molecular drug target, since it is not a canonical, native molecule nor a standard, therapeutically targeted receptor/enzyme, but a chimeric research tool. If you want information about the **entire Prime editor complex as a therapeutic genome editing system**, that is a synthetically engineered entity comprising nCas9(H840A), M-MLV RT, and pegRNA, none of which work as targets in the traditional pharmacological sense.

Other names

Prime editor reverse transcriptaseM-MLV reverse transcriptaseMoloney murine leukemia virus RT

Reverse transcription: synthesizes DNA from an RNA template sequence specified in pegRNA[2][3][9][10].